nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Accessing health care autistically: a routine nasojejunal tube replacement
|
Larrington-Spencer, Harrie |
|
|
8 |
9 |
p. 787-788 |
artikel |
2 |
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis
|
Dajti, Elton |
|
|
8 |
9 |
p. 816-828 |
artikel |
3 |
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kliewer, Kara L |
|
|
8 |
9 |
p. 803-815 |
artikel |
4 |
Britta Siegmund: answering the big questions in IBD
|
Kirby, Tony |
|
|
8 |
9 |
p. 786 |
artikel |
5 |
Clinical application of circulating tumour DNA in colorectal cancer
|
Loft, Matthew |
|
|
8 |
9 |
p. 837-852 |
artikel |
6 |
Correction to Lancet Gastroenterol Hepatol 2023; published online July 4. https://doi.org/10.1016/S2468-1253(23)00157-7
|
|
|
|
8 |
9 |
p. e7 |
artikel |
7 |
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
|
Parigi, Tommaso Lorenzo |
|
|
8 |
9 |
p. 853-859 |
artikel |
8 |
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
|
Yuen, Man-Fung |
|
|
8 |
9 |
p. 790-802 |
artikel |
9 |
Is it time for a paradigm shift in treatment guidelines for chronic hepatitis B?
|
Johannessen, Asgeir |
|
|
8 |
9 |
p. 784 |
artikel |
10 |
More is not always better for novel hepatitis B therapies
|
Lens, Sabela |
|
|
8 |
9 |
p. 772-773 |
artikel |
11 |
NAFLD and liver-related events: does type 2 diabetes have a key role?
|
Vilar-Gomez, Eduardo |
|
|
8 |
9 |
p. 777-778 |
artikel |
12 |
Poor disease knowledge among people living with hepatitis B in The Gambia and Tanzania
|
Vo-Quang, Erwan |
|
|
8 |
9 |
p. 783-784 |
artikel |
13 |
Poor Little Sick Girls: A Love Letter to Unacceptable Women
|
Islam, Tanzina |
|
|
8 |
9 |
p. 788-789 |
artikel |
14 |
Rare cause of dysphagia in a young woman
|
Alwali, Ahmed |
|
|
8 |
9 |
p. 860 |
artikel |
15 |
Research in Brief
|
Baker, Holly |
|
|
8 |
9 |
p. 785 |
artikel |
16 |
Spleen stiffness to identify clinically significant portal hypertension
|
Ripoll, Cristina |
|
|
8 |
9 |
p. 775-776 |
artikel |
17 |
Targeting type 2 immune responses to treat eosinophilic gastritis
|
Burns, Grace L |
|
|
8 |
9 |
p. 773-775 |
artikel |
18 |
The top 10 research priorities for pancreatitis: findings from a James Lind Alliance priority setting partnership
|
Mitra, Vikramjit |
|
|
8 |
9 |
p. 780-782 |
artikel |
19 |
Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis
|
Huang, Daniel Q |
|
|
8 |
9 |
p. 829-836 |
artikel |
20 |
Unsilencing liver disease
|
The Lancet Gastroenterology & Hepatology, |
|
|
8 |
9 |
p. 771 |
artikel |
21 |
Viral hepatitis in Asia-Pacific: a post-COVID-19 reset
|
Wallace, Jack |
|
|
8 |
9 |
p. 778-780 |
artikel |